… For patients with moderate-to-severe COPD, long-acting … Inhaled long-acting β 2 -agonists
(LABAs) have been … the role and future of long-acting β 2 -agonists (LABAs) in the …

… For over a decade, the Food and Drug Administration (FDA) and the medical community have
discussed how to safely use long-acting beta-agonists (LABAs) — drugs designed to provide …

… inhaled long acting beta agonists with regular use of inhaled short acting beta agonists in …
from the regular use of inhaled long acting beta agonists compared with inhaled short acting …

… Plasmalemma diffusion microkinetic theory of the duration of action of beta2-adrenoceptor
agonists To understand the duration of action of beta2-adrenoceptor agonists, we propose …

… Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients
using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators. …

… of action. The pharmacologic profiles of these drugs result from prolonged activation of beta
2-adrenoceptors, leading to long-… The long-acting beta 2-agonists represent a therapeutic …

… How do we reconcile in clinical practice the established beneficial effects of long-acting
beta-agonists on asthma control with their rare potential for contributing to severe illness or …

… To estimate the long-term benefits of combination long-acting β-agonists (LABAs) and … )
and those who were not receiving inhaled long-acting anticholinergic medication (difference in …

… long-acting beta-agonists (LABAs). The meeting is described in detail in a Perspective in
this issue of the Journal by Kramer, 1 who points out that decision making by the advisers and …

… It is unclear whether long-acting β-agonists with concomitant inhaled corticosteroids
increase asthma-related intubations and deaths. We pooled data on long-acting β-agonists with …